Advertisement

Drugs in R & D

, Volume 5, Issue 6, pp 343–348 | Cite as

Icatibant

HOE 140, JE 049, JE049
Adis R&D Profile

Abstract

Icatibant [HOE 140, JE 049] is a potent, specific and selective peptidomimetic bradykinin β2-receptor antagonist. It has a modified peptide structure, and is the first bradykinin receptor antagonist to act on the guinea-pig trachea without demonstrating agonist effects. Icatibant was originated by Hoechst Marion Roussel (now Sanofi-Aventis).

Jerini is seeking a partner for development and marketing of icatibant for the treatment of refractory ascites in liver cirrhosis, angioedema and burns.

In August 2004, Aventis merged with Sanofi-Synthelabo to form Sanofi-Aventis.

Icatibant has shown an excellent safety profile in phase I studies. In December 2003, Jerini demonstrated positive results in the phase IIa study. Results obtained were statistically significant and clinically relevant. At the BIO 2004 International Annual Convention (BIO-2004) [San Francisco, CA, USA; 6–9 June 2004], Jerini reported plans to initiate phase IIb trials in this indication in the second half of...

Keywords

Bradykinin Angioedema Quinapril Hereditary Angioedema Orphan Drug Status 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Profiles of participating companies. BIO 2004: Annual International Convention. Business Forum: 6 Jun 2004Google Scholar
  2. 2.
    Jerini AG. Jerini Concludes its Icatibant Phase II Study in Hereditary Angioedema with Positive Results. Media Release: 26 Aug 2004. Available from URL: http://www.jerini.com Google Scholar
  3. 3.
    Jerini AG. Jerini Initiates Pivotal Registration Study for Icatibant in Hereditary Angioedema. Media Release: 8 Sep 2004. Available from URL: http://www.jerini.com Google Scholar
  4. 4.
    Jerini AG. Jerini Receives FDA Fast Track Designation for Icatibant in Hereditary Angioedema. Media Release: 22 Jul 2004. Available from URL: http://www.jerini.com Google Scholar
  5. 5.
    Jerini. Jerini Has Been Granted Orphan Drug Designation by U.S. FDA for Icatibant, JE049, to Treat Patients with Angioedema. Media Release: 18 Nov 2003. Available from URL: http://www.jerini.com Google Scholar
  6. 6.
    Proud D. Clinical application of kinin antagonists. Canadian Journal of Physiology and Pharmacology 72 (Suppl. 2): 19, 1994Google Scholar
  7. 7.
    Jerini. Jerini Announces Positive Results in a Subcutaneous Bioavailability Study for Icatibant. Media Release: 14 Apr 2004. Available from URL: http://www.jerini.com Google Scholar
  8. 8.
    Wirth KJ, Gehring D, Schölkens BA. Effect of Hoe 140 on bradykinin-induced bronchoconstriction in anesthetized guinea pigs. American Review of Respiratory Disease 148: 702–706, Sep 1993PubMedCrossRefGoogle Scholar
  9. 9.
    Wirth KJ, Gehring D, Schölkens BA. Effect of HOE 140 on bradykinin-induced bronchoconstriction in anaesthetised guinea pigs. Naunyn-Schmiedeberg’s Archives of Pharmacology 344 (Suppl. 2): R141, 1991Google Scholar
  10. 10.
    Jerini. Jerini’s Bradykinin Antagonist Icatibant Shows Promise in Treatment of Refractory Ascites in Liver Cirrhosis in a Phase II Study. Media Release: 2 Dec 2003. Available from URL: http://www.jerini.com Google Scholar
  11. 11.
    Sun W, Wainwright CL. The potential antiarrhythmic effects of exogenous and endogenous bradykinin in the ischaemic rat heart in vivo. Coronary Artery Disease 5: 541–550, Jun 1994PubMedGoogle Scholar
  12. 12.
    Gaudron P, Hu K, Zdrojewski T, et al. AT1-receptor blocker versus angiotensin converting enzyme inhibitor in acute myocardial Role of dosage and bradykinin on remodelling, hemodynamics and mortality in the rat model. Journal of the American College of Cardiology 31 (Suppl. 2A): 311, Feb 1998CrossRefGoogle Scholar
  13. 13.
    Proud D, Reynolds CJ, Broomfield J. Bradykinin effects in guinea pig tracheal epithelial cells are mediated through a gB2 kinin receptor and can be inhibited by the selective antagonist Hoe 140. Journal of Pharmacology and Experimental Therapeutics 264: 1124–1131, Mar 1993PubMedGoogle Scholar
  14. 14.
    Hock FJ, Wirth K, Albus U. Hoe 140, a new potent and long acting bradykinin-antagonist: in vitro studies. British Journal of Pharmacology 102: 769–773, Mar 1991PubMedCrossRefGoogle Scholar
  15. 15.
    Rhaleb N-E, Rouissi N, Jukic D. Pharmacological characterization of a new highly potent ß2 receptor antagonist (HOE 140: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8]bradykinin). European Journal of Pharmacology 210: 115–120, 14 Jan 1992PubMedCrossRefGoogle Scholar
  16. 16.
    Félétou M, Germain M, Thurieau C. Agonistic and antagonistic properties of the bradykinin ß2 receptor antagonist, Hoe 140, in isolated blood vessels from different species. British Journal of Pharmacology 112: 683–689, Jun 1994PubMedCrossRefGoogle Scholar
  17. 17.
    Sakamoto T, Sun J, Barnes PJ, et al. Effect of a bradykinin receptor antagonist, HOE 140, against bradykinin- and vagal stimulation-induced airway responses in the guinea-pig. European Journal of Pharmacology 251: 137–142, 14 Jan 1994PubMedCrossRefGoogle Scholar
  18. 18.
    Sakamoto T, Elwood W, Barnes PJ. Evaluation of a bradykinin antagonist (HOE 140) against bradykinin and platelet activating factor induced airway responses in the guinea pig. Thorax 47: 241P, Mar 1992Google Scholar
  19. 19.
    Sakamoto T, Elwood W, Barnes PJ, et al. Effect of Hoe 140, a new bradykinin receptor antagonist, on bradykinin- and platelet- activating factor-induced bronchoconstriction and airway microvascular leakage in guinea pig. European Journal of Pharmacology 213: 367–373, 31 Mar 1992PubMedCrossRefGoogle Scholar
  20. 20.
    Sakamoto T, Elwood W, Barnes PJ. Effect of a novel bradykinin antagonist (HOE140) against bradykinin, platelet activating factor, sodium metabisulfite and allergen induced airway responses in the guinea pig. American Review of Respiratory Disease 145: A859, Apr 1992Google Scholar
  21. 21.
    Wirth K, Hock FJ, Albus U. Hoe 140, a new potent and long acting bradykinin-antagonist: in vivo studies. British Journal of Pharmacology 102: 774–777, Mar 1991PubMedCrossRefGoogle Scholar
  22. 22.
    Damas J, Remacle-Volon G. Influence of a long-acting bradykinin antagonist, Hoe 140, on some acute inflammatory reactions in the rat. European Journal of Pharmacology 211: 81–86, 28 Jan 1992PubMedCrossRefGoogle Scholar
  23. 23.
    Featherstone RL, Parry JE, Church MK. The effects of kinin antagonism with HOE 140 on the response of guinea-pigs to allergen. Clinical and Experimental Allergy 23 (Suppl. 1): 32, Feb 1993Google Scholar
  24. 24.
    Austin CE, Foreman JC, Scadding GK. Reduction by Hoe 140, the B2 kinin receptor antagonist, of antigen-induced nasal blockage. British Journal of Pharmacology 111: 969–971, Apr 1994PubMedCrossRefGoogle Scholar
  25. 25.
    Jerini AG. Jerini Announces Positive Phase II Study Results with Icatibant for the Treatment of Hereditary Angioedema. Media Release: 13 Jan 2004. Available from: URL: http:// www.jerini.com Google Scholar
  26. 26.
    Avery J, Barber C. A topical bradykinin antagonist first clinical trial of icatibant nasal spray in seasonal allergic rhinitis. Allergy and Clinical Immunology News (Suppl. 2): 415, 1994Google Scholar

Copyright information

© Adis Data Information BV 2004

Personalised recommendations